TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers analyzed genetic data from nearly 450,000 people and identified 42 DNA regions associated with Alzheimer’s risk among APOE4 carriers, including 29 not previously reported in this context. The findings point to oligodendrocytes and genes including TNS3 and CISD1 as possible research targets, but they require further validation and may not apply across ancestries.
Researchers analyzing genetic data from nearly 450,000 people identified DNA regions associated with protection from Alzheimer’s disease among people carrying the APOE4 risk variant, according to a study published in Alzheimer’s & Dementia. The findings highlight genes linked to oligodendrocytes, cells that help nerve fibers transmit signals, as possible leads for research—not established treatments.
Washington University in St. Louis researcher Michael Belloy and colleagues looked for genetic differences among people with one or two copies of APOE4, a common variant associated with elevated Alzheimer’s risk. The team reported 42 DNA regions linked to APOE4 status: 13 that had been identified previously and 29 newly identified in this analysis. The study focused on people who carried APOE4 but had not developed Alzheimer’s, seeking clues to why increased genetic risk does not lead to the disease in everyone.
The researchers also examined gene activity in post-mortem brain tissue from 424 donors. Their analysis suggested that many genes associated with protection were active in oligodendrocytes, which form insulating sheaths around neurons and support efficient electrical signaling. Belloy highlighted TNS3 and CISD1 as potential risk modifiers: TNS3 is involved in oligodendrocyte maturation and survival, while CISD1 has a role in their metabolism.
The results do not show that either gene prevents Alzheimer’s or that changing its activity would benefit patients. Belloy told Being Patient that the genes appear promising as ways to investigate risk linked to APOE4. The study’s authors say the signals need experimental testing and independent validation before researchers can establish how they work or whether they could inform treatment.
Oligodendrocytes Emerge as Research Leads
APOE4 is a major inherited risk factor for Alzheimer’s, but carrying it does not make the disease inevitable. Finding genetic differences associated with lower risk among carriers could help researchers identify biological processes that buffer against that risk. The reported link to oligodendrocytes broadens attention beyond neurons and the processes most commonly discussed in Alzheimer’s research.
That biological lead is not yet a clinical result. The study does not establish that the identified genes cause protection, nor does it test a drug or measure whether activating these genes changes outcomes. The potential value for readers is therefore in the research direction: if later work confirms the signals and explains their effects, they could help identify new targets for drug development or refine understanding of why risk varies between people.
Some of the genes may be “druggable” because their encoded proteins could, in principle, be targeted by medicines. But Being Patient reported that there are currently no FDA-approved drugs targeting TNS3 or CISD1 that can simply be repurposed for Alzheimer’s. Any treatment implications remain speculative until laboratory and clinical research supports them.
As an affiliate, we earn on qualifying purchases.
Why APOE4 Does Not Tell the Whole Story
APOE4 is widely regarded as the strongest common genetic risk factor for Alzheimer’s, but it is not a diagnosis and does not act alone. The Being Patient report says risk is higher for people with one or two copies, while also noting that many carriers do not develop the disease. Its article cites an estimate that about 60% of people with two copies develop Alzheimer’s over their lifetimes; that figure is a population estimate, not a prediction for any individual.
Researchers have previously studied rare genetic variants that may delay Alzheimer’s in people with inherited forms of the disease. One example discussed in the report is the Christchurch variant, associated with a Colombian woman who remained cognitively healthy into her 70s despite a genetic form that typically causes symptoms much earlier. The report also notes that questions have been raised about the reliability of some research on that variant. The new study addresses a broader question: whether additional genetic differences help explain variation in risk among APOE4 carriers.
To connect genetic signals with possible biological processes, the researchers paired the large genetic analysis with data on gene activity in donated brain tissue. That second analysis can suggest which cell types merit further study, but tissue collected after death—especially from people who died in later disease stages—may not reveal what was happening earlier in Alzheimer’s. The report says the clinical diagnoses in the genetic dataset also had limits: only 40% were biomarker-confirmed.
“Ultimately, we found a set of genes that look promising to counter Alzheimer’s disease risk due to APOE4.”
— Michael Belloy, assistant professor at Washington University in St. Louis, speaking to Being Patient
Key Signals Still Need Validation
The reported genetic associations do not by themselves establish that the identified variants or genes directly protect against Alzheimer’s. Researchers must test whether the signals hold in independent datasets and investigate their effects experimentally. The study population was mostly of European ancestry, so it is not clear whether the results apply to other populations.
There are also limits to the clinical and brain-tissue evidence. The report says just 40% of people in the genetic data had biomarker confirmation of Alzheimer’s; some diagnoses may therefore have been incorrect. And because the donated brain tissue came from people who had died, gene activity in those samples may not reflect changes in early disease. It remains unclear how large any protective effect is, when it acts, and whether it could be safely influenced by a treatment.
Replication and Laboratory Testing Ahead
The next steps are independent validation of the genetic associations and experimental studies to test how candidate genes such as TNS3 and CISD1 affect oligodendrocytes and Alzheimer’s-related processes. Studies involving people from a wider range of ancestries would help establish whether the findings generalize beyond the largely European-ancestry dataset.
Researchers would also need to determine whether the signals operate early in disease, whether they are causal, and whether changing the relevant biological pathways is feasible and safe. The report does not describe a treatment trial based on these findings or provide a timeline for clinical testing. For now, the work is a set of research leads; any drug-development or patient-care implications depend on results from future studies.
Key Questions
Does carrying APOE4 mean someone will develop Alzheimer’s?
No. APOE4 raises risk, but it does not determine an individual’s outcome. Many people who carry one or two copies do not develop Alzheimer’s, and risk estimates cannot predict what will happen to a particular person.
Which genes did the study identify as possible protective factors?
The report highlights TNS3 and CISD1 as possible risk modifiers among APOE4 carriers. The study identified genetic regions associated with risk, but further work is needed to confirm the genes’ roles and whether they directly contribute to protection.
What role might oligodendrocytes play?
Oligodendrocytes form fatty sheaths around nerve fibers that help neurons send electrical signals efficiently. The researchers found that many genes associated with protection were active in these cells, making them a possible focus for further study, not a confirmed treatment target.
Can these findings be used to prevent or treat Alzheimer’s now?
No. The study did not test a treatment, and the genetic signals have not been fully validated. The findings are early research leads; they do not establish that a medicine targeting these genes would work or be safe.
Do the results apply to every ancestry group?
That is not yet known. The study participants were mostly of European ancestry, so researchers need to test the findings in more diverse populations before concluding that they generalize broadly.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
